Genmab A/S (GMAB) Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 12-month price targets for Genmab A/S's shares. Their GMAB share price forecasts range from $31.00 to $3,600.00. On average, they expect the company's stock price to reach $632.62 in the next twelve months. This suggests a possible upside of 1,498.7% from the stock's current price.
View analysts price targets for GMAB or view top-rated stocks among Wall Street analysts.

Genmab A/S's stock was trading at $42.38 at the start of the year. Since then, GMAB shares have decreased by 6.6% and is now trading at $39.57.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our GMAB earnings forecast.

Genmab A/S (NASDAQ:GMAB) posted its earnings results on Wednesday, November, 10th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.10. The business had revenue of $366.25 million for the quarter, compared to analysts' expectations of $341.46 million. Genmab A/S had a trailing twelve-month return on equity of 19.67% and a net margin of 34.34%. During the same period in the previous year, the firm posted $0.13 EPS.

ETFs with the largest weight of Genmab A/S (NASDAQ:GMAB) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), First Trust NYSE Arca Biotechnology Index Fund (FBT), iShares Biotechnology ETF (IBB), Goldman Sachs Future Health Care Equity ETF (GDOC), WisdomTree BioRevolution Fund (WDNA), BlackRock Future Health ETF (BMED), Pacer Trendpilot International ETF (PTIN) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Genmab A/S updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.94 billion-$2.13 billion, compared to the consensus revenue estimate of $2.31 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

(GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Genmab A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.80%), Macquarie Group Ltd. (0.53%), Wellington Management Group LLP (0.37%), 1832 Asset Management L.P. (0.34%), First Trust Advisors LP (0.19%) and Envestnet Asset Management Inc. (0.17%).

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GMAB stock can currently be purchased for approximately $39.57.

Genmab A/S (NASDAQ:GMAB) has a market capitalization of $26.11 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.11 on an earnings per share basis.

The company employs 1,660 workers across the globe.

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com.